Search research articles
Contact Us
Filters
Showing results (1-10 of 83) with videos related to
Page
of 9
Sort By:
Vaccine
|
September 22, 2011
Therapeutic cancer vaccines: why so few randomised phase III studies reflect the initial optimism of phase II studies
Angus G Dalgleish
Expert Review of Vaccines
|
December 21, 2004
Cancer vaccines as a therapeutic strategy
Angus G Dalgleish
Expert Review of Vaccines
|
February 3, 2006
Immunotherapy and the development of cancer vaccines
Angus G Dalgleish
Immunotherapy
|
March 26, 2015
Rationale for combining immunotherapy with chemotherapy
Angus G Dalgleish
Expert Review of Anticancer Therapy
|
November 26, 2019
Why do the majority of patients not respond at all, or only partially or transiently, to immunotherapy?
Angus G Dalgleish
Cancer Immunology, Immunotherapy : CII
|
March 4, 2018
The Third Institute for Cancer Vaccines and Immunotherapy (ICVI) symposium on immunotherapy: May 12-13, 2017, Royal Society, London, UK
Angus G Dalgleish
Human Vaccines & Immunotherapeutics
|
January 28, 2015
Vaccines versus immunotherapy: overview of approaches in deciding between options
Angus G Dalgleish
Cancer Treatment and Research
|
April 14, 2006
Inflammation and cancer: the role of the immune response and angiogenesis
Angus G Dalgleish, Ken O'Byrne
Clinical Medicine (London, England)
|
July 16, 2008
Pathogenesis of HIV: non-specific immune hyperactivity and its implications for vaccines
Martin Cadogan, Angus G Dalgleish
Cancer Informatics
|
March 18, 2010
The power of the web in cancer drug discovery and clinical trial design: research without a laboratory?
Christine Galustian, Angus G Dalgleish
Page
of 9
Search research articles
Search
Showing results (1-10 of 83) with videos related to
Sort By:
Page
of 9
Vaccine
|
September 22, 2011
Therapeutic cancer vaccines: why so few randomised phase III studies reflect the initial optimism of phase II studies
Angus G Dalgleish
Expert Review of Vaccines
|
December 21, 2004
Cancer vaccines as a therapeutic strategy
Angus G Dalgleish
Expert Review of Vaccines
|
February 3, 2006
Immunotherapy and the development of cancer vaccines
Angus G Dalgleish
Immunotherapy
|
March 26, 2015
Rationale for combining immunotherapy with chemotherapy
Angus G Dalgleish
Expert Review of Anticancer Therapy
|
November 26, 2019
Why do the majority of patients not respond at all, or only partially or transiently, to immunotherapy?
Angus G Dalgleish
Cancer Immunology, Immunotherapy : CII
|
March 4, 2018
The Third Institute for Cancer Vaccines and Immunotherapy (ICVI) symposium on immunotherapy: May 12-13, 2017, Royal Society, London, UK
Angus G Dalgleish
Human Vaccines & Immunotherapeutics
|
January 28, 2015
Vaccines versus immunotherapy: overview of approaches in deciding between options
Angus G Dalgleish
Cancer Treatment and Research
|
April 14, 2006
Inflammation and cancer: the role of the immune response and angiogenesis
Angus G Dalgleish, Ken O'Byrne
Clinical Medicine (London, England)
|
July 16, 2008
Pathogenesis of HIV: non-specific immune hyperactivity and its implications for vaccines
Martin Cadogan, Angus G Dalgleish
Cancer Informatics
|
March 18, 2010
The power of the web in cancer drug discovery and clinical trial design: research without a laboratory?
Christine Galustian, Angus G Dalgleish
Page
of 9